Gastroenterology News

BOSTON — A virtual treatment program that coordinates care with local providers improved therapy for children and adolescents with hepatitis C virus in the United Kingdom, according to a presentation at The Liver Meeting.

Mycophenolic acid, sirolimus and steroids were associated with an increased risk for COVID-19-related hospitalization among those who underwent kidney, liver, heart or lung transplant, data from JAMA Network Open showed.

The FDA has granted orphan drug designation to Ocelot Bio’s OCE-205, a mixed vasopression 1a receptor agonist-antagonist peptide for the treatment of ascites resulting from all causes except cancer, according to a company release.

BOSTON — Implementation of universal hepatitis C virus screening at cancer centers and corresponding care may positively affect HCV elimination targets and improve public health outcomes, according to a presentation at The Liver Meeting.

Updated AGA clinical practice guidelines reiterated the society’s stance that there is little data to support the recommendation that all patients should stop glucagon-like peptide-1 receptor agonists prior to elective endoscopy procedures.

The AGA has published the first comprehensive guideline on the management of pouchitis and other inflammatory pouch disorders among patients with ulcerative colitis who have undergone ileal pouch-anal anastomosis surgery.

BOSTON — There is a reduction in syringe sharing when methadone providers are spread out near areas with the greatest density of people who inject drugs, according to research presented at The Liver Meeting.

BOSTON — In this video, Norah Terrault, MD, MPH, FAASLD, discusses data from The Liver Meeting on treatment of hepatitis C virus infection among individuals with hepatocellular carcinoma.

Topline findings from the eAArly DETECT trial showed Mainz Biomed’s novel mRNA biomarkers boasted a sensitivity and specificity of 97% for detection of colorectal cancer, and an 82% sensitivity for advanced adenomas detection.

In a Healio video exclusive, Edward V. Loftus Jr., MD, highlighted how rebranding nonalcoholic fatty liver disease as metabolic dysfunction-associated steatotic liver disease offers a “positive diagnosis” without the associated stigma.